Kristie Kahl

Philadelphia

Vice President of Content at MJH Life Sciences

I'd rather be someone's shot of whiskey than everyone's cup of tea

Featured in: Favicon

mjhlifesciences.com Favicon

healio.com Favicon

newsbreak.com Favicon

ajmc.com

valdostadailytimes.com Favicon

heraldcourier.com Favicon

cancernetwork.com Favicon

onclive.com Favicon

curetoday.com Favicon

dailyamerican.com + 7 more

Articles

Addition of Toripalimab to Induction Improves PFS in Nonresectable NSCLC

5 days ago | onclive.com | Kristie Kahl

Induction toripalimab plus chemotherapy for 2 cycles, compared with chemotherapy alone, followed by definitive chemoradiotherapy and consolidation, significantly improved progression-free survival (PFS) in patients with bulky, unresectable stage III non–small cell lung cancer (NSCLC), according to data from the InTRist study (NCT05888402) presented at the 2025 ASCO Annual Meeting.1“Toripalimab is a very promising strategy for patients with bulky, unresectable tumors.
Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC

6 days ago | onclive.com | Kristie Kahl

Treatment with sevabertinib (BAY 2927088) may lead to high and comparable objective response rates (ORRs) among patients with HER2-mutant non–small cell lung cancer (NSCLC) who were pretreated but naive to HER2-targeted therapy, or had not received any treatment for advanced disease, according to data from the phase 1/2 SOHO-01 trial (NCT05099172) presented at the 2025 ASCO Annual Meeting.
Fruquintinib Combo Exhibits Frontline Efficacy in Advanced ESCC

6 days ago | cancernetwork.com | Kristie Kahl

Fruquintinib (Fruzaqla) plus camrelizumab, paclitaxel liposome, and nedaplatin exhibited significant efficacy outcomes and an acceptable safety profile as a frontline treatment for patients with advanced esophageal squamous cell carcinoma (ESCC), according to findings from a phase 2 study (NCT06010212) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC

1 week ago | onclive.com | Kristie Kahl

Frontline treatment with fruquintinib (Fruzaqla) plus camrelizumab, paclitaxel liposome, and nedaplatin elicited responses with an acceptable safety profile in patients with advanced esophageal squamous cell carcinoma (ESCC), according to findings from a phase 2 study (NCT06010212) presented during the 2025 ASCO Annual Meeting.
Personalizing Prostate Cancer Care With Genetic Testing, PARP Inhibitors

1 week ago | curetoday.com | Kristie Kahl

Precision medicine has revolutionized the treatment of prostate cancer, in particular the use of genetic testing for specific DNA damage repair genes to determine which patients would benefit from treatment with PARP inhibitors. Therefore, understanding these advancements is crucial for patients, as they offer more personalized and effective treatment strategies. “[Treatment is] not one-size-fits-all when it comes to managing patients with prostate cancer.
2025 ASCO Annual Meeting: The Show and After Show

2 weeks ago | cancernetwork.com | Kristie Kahl

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30 to June 3, in Chicago, is poised to feature practice-changing data across various cancer types. The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec offer a glimpse at some of the presentations guaranteed to spark one’s curiosity, spur debate, and enhance the field even further, highlighting key areas of anticipated interest for oncology providers.
Prostate Cancer Treatment Options: Common Questions in Focal Therapy, Surgery

2 weeks ago | curetoday.com | Kristie Kahl

Understanding one’s treatment options is a crucial first step in making informed decisions about care. When the cancer is contained within the prostate gland, meaning it hasn't spread to other parts of the body, localized treatments are often the primary approach. Two key categories of localized treatment are surgery and focal therapy. Surgery, typically a radical prostatectomy, involves the complete removal of the prostate gland.
Answers to Frequently Asked Questions About Prostate Cancer Risk, Treatment

2 weeks ago | curetoday.com | Kristie Kahl

Navigating a prostate cancer diagnosis involves understanding a range of factors, including one’s individual risk profile and the various treatment options available.
Patient-Centered Communication Drives Supportive Care Needs in Incurable Cancer

1 month ago | oncnursingnews.com | Kristie Kahl

The Primary Palliative Care Communication Intervention (PRECURSOR) may improve the psychosocial experiences of patients with incurable gynecologic cancer and their caregivers in the outpatient setting, according to results of a pilot study presented at the 50th Annual ONS Congress. “As cancer treatments have advanced over the last few decades, we have increasing numbers of patients living with incurable cancer as a chronic condition.
Nurse-Led Sessions Enhance Supportive Care for Patients on Clinical Trials

1 month ago | oncnursingnews.com | Kristie Kahl

A nurse-led intervention to address supportive care concerns of patients with cancer taking part in an early phase clinical trial appeared to be useful, effective, and relevant, according to a pilot study presented at the 50th Annual ONS Congress.